Danish pharmaceutical leader Novo Nordisk has revised down its full-year 2025 sales growth forecast for its flagship GLP-1 products Wegovy and Ozempic to 8%–14%, from an earlier 13%–21% projection. The company cited sustained pressure from low-cost compounded versions of semaglutide approved during earlier shortages as a major drag on sales. Concurrently, operating profit expectations were lowered. This guidance cut prompted a sharp decline in Novo’s shares, erasing over $60 billion in market value. Amidst these developments, longtime insider Maziar Mike Doustdar was named the incoming CEO, succeeding Lars Fruergaard Jørgensen, with organizational restructuring accompanying the leadership change.